Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Pediatric AIDS prevention trial that helped pave way for vision of AIDS-free generation is part of pioneering researcher’s story
This article originally appeared on the Elizabeth Glaser Pediatric AIDS Foundation blog Experts in Focus: Dr. Laura Guay By Chelsea Bailey | April 15, 2014 “When […]
For a decade and a half after the World Health Organization launched the expansion of directly observed treatment for tuberculosis, strides against the disease, highlighted by […]
Along with three new grants targeting neglected diseases carried by “kissing bugs” “snail carrying worms” and “gender-bending bacteria,” a second round of grants from the private-public […]
While development assistance to middle and low-income countries for global health reached an all-time high last year, assistance for “the main infectious diseases, HIV/AIDS, tuberculosis, and […]